Background: The ability of radiation to enhance antitumor immunity under specific experimental conditions is well established. Here, we explore preclinical data and the rationale for combining different radiation doses and fractions with immune checkpoint blockade immunotherapy.
HNSCC. 5 Greater than two-thirds of all patients with HNSCC will receive ionizing radiation at some point during their treatment. 6 Significant preclinical data suggests that ionizing radiation is additive or synergistic with different forms of immunotherapy, including checkpoint inhibition. However, close inspection reveals that most combinations demonstrating a significant combinatorial effect utilize high-dose single or hypofractionated ionizing radiation regimens, with mixed results observed with combinations utilizing low-dose fractionated regimens, potentially due to immune suppression after many fractions of daily ionizing radiation. [7] [8] [9] [10] [11] Here, we review the historical contexts for the use of daily fractionated ionizing radiation in HNSCC, how an antitumor immune response develops, how ionizing radiation alters the function of individual components of this response, and the preclinical and clinical data supporting the combination of ionizing radiation and immune checkpoint blockade.
| Why do we use fractionated ionizing radiation for head and neck cancer?
Historically, the antitumor effects of ionizing radiation have been attributed to its direct tumor cell cytotoxic effects. Many well performed, prospective clinical trials have established improved survival and treatment tolerability in patents with locoregionally advanced HNSCC after fractionated ionizing radiation, with the most common treatment schema being 2 Gy/day fractions, 5 days/week for 35 total days (70 Gy total), although various accelerated and hyperfractionation schedules have been studied. 5, 12 In this context of upfront treatment of advanced HNSCC, several principles have emerged to potentially explain why fractionated ionizing radiation controls tumor growth. Commonly referred to as the "4Rs of fractionated radiotherapy," 13 these include:
repair (fractionated ionizing radiation gives normal tissues, which repair faster than tumor tissues, time to repair between doses); repopulation (based on hypothesis that damaged tumor cells will be replaced by nondamaged tumor cells between fractions); reoxygenation (ionizing radiation requires oxygen for production of free radicals and fractionation allows for variation of hypoxic regions within tumors over time); and redistribution (fractionation allows more tumor cells to cycle into G2/M of the cell cycle where they are the most sensitive to ionizing radiation).
In our new era of using immunotherapy to reverse adaptive immune resistance in HNSCC, how different dose and fractionation ionizing radiation schemas alter antitumor immunity must be considered. Daily, low-dose, fractionated ionizing radiation for HNSCC results in peripheral lymphopenia and the degree of drop in peripheral lymphocyte levels correlates to disease-free survival after treatment with either ionizing radiation alone or ionizing radiation plus chemotherapy. [14] [15] [16] Does this mean that how we give ionizing radiation to patients with advanced HNSCC is immunosuppressive? How ionizing radiation alters antitumor immunity at the level of the tumor microenvironment can be very complex and peripheral lymphopenia may not be a good surrogate measure of local antitumor immunity. To begin to understand these complex differences, we must understand how an effective antitumor immune response develops and how ionizing radiation alters the function of these critical cell types within the tumor microenvironment.
| What effect does ionizing radiation have on the tumor microenvironment?
Although hematopoietic cells are exquisitely sensitive to low doses of ionizing radiation, the cumulative effects of different ionizing radiation doses and fractionation schemas on these cells as they circulate through the tumor microenvironment are less well understood. Immune modulation within the tumor microenvironment in response to ionizing radiation is complex due to circulation and tumor repopulation of immune cells, changes in tumor oxygenation, and numerous direct effects that ionizing radiation may have on tumor and stromal cells. Here, we review known alterations induced by ionizing radiation on cellular subsets present within the tumor microenvironment. Critical known alterations in the function of these cellular subsets after ionizing radiation are summarized in Figure 1 .
| Dendritic cells
Dendritic cells are effective antigen-capturing cells in their immature form. Upon encountering maturation signals, they differentiate into effective antigen-presenting dendritic cells and become specialized in stimulating T cells through expression of appropriate costimulatory molecules. The dendritic cell maturation can be triggered by a variety of "danger" signals (damage-associated molecular patterns) released by pathogens as well as damaged or stressed host cells. 17, 18 Ionizing radiation may induce immunogenic cell death leading to increased tumor cell surface calreticulin and release of damage-associated molecular patterns, such as high-mobility group box 1 (HMGB1) and ATP. 19, 20 Calreticulin on the surface of tumor cells or cellular debris increases phagocytosis by dendritic cells, whereas HGMB1 acts as a chemoattractant and activator of immature dendritic cells. These alterations seem to activate dendritic cells, although effects seem to be ionizing radiation dose, fractionation, and model dependent.
In vitro, immature dendritic cells coincubated with supernatant from SC480 colorectal tumor cells irradiated with 2 Gyx5 or 5 Gyx3 increased expression of dendritic cell maturation markers CD80 and CD83 and expression of proinflammatory cytokines interleukin (IL)-12p70, IL-8, IL-6, and tumor necrosis factor alpha (TNF-a). 21 However, direct exposure of dendritic cells isolated from peripheral blood mononuclear cells to 30 Gyx1 reduced expression of CD86, CD80, and Human Leukocyte Antigen -antigen D Related (HLA-DR) with resulting decreased capacity for stimulating T cell proliferation. 22 In vivo results more consistently demonstrate enhanced dendritic cell function after ionizing radiation. Lugade et al 10 demonstrated an increased accumulation and activation of dendritic cells within the tumor draining lymph node when B16-OVA tumor cells were exposed to either 15 Gyx1 or 3 Gyx5 with greater effects observed with 15 Gyx1. Similar results were observed by Lee et al 9 after
B16-SIY tumors were exposed to 20 Gyx1. Strong evidence for the importance of functional dendritic cells within the tumor microenvironment after ionizing radiation comes from studies in genetically altered mice with dysfunctional dendritic cells or type I interferon (IFN) responses. Cytosolic sensing of DNA within dendritic cells and subsequent stimulator of interferon genes (STING)-dependent production of type I IFN seems to be critical for cross-priming of antigen-specific T cell responses, and any alteration of this DNA sensing pathway or type I IFN response within host cells abrogates tumor control after ionizing radiation. [23] [24] [25] Cumulatively, preclinical evidence suggests that, although direct ionizing radiation exposure may be detrimental to dendritic cells, ionizing radiation may enhance immunogenic tumor cell death and indirectly activate dendritic cells within the tumor microenvironment through enhanced antigen release, availability of damageassociated molecular patterns, and ultimately STINGdependent type I IFN signaling resulting in enhanced antigen cross-presentation.
| T-lymphocytes
Although natural killer (NK) cells and even innate immune cells can exert antitumor effects, 26, 27 T-lymphocytes are largely credited with having the ability to detect and eradicate malignant cells. Lymphocytes are highly sensitive to ionizing radiation-induced death and lymphopenia is a side effect of fractionated radiotherapy, and this effect seems to be fractionation dependent. 16, 28 Yet, cumulative effects of therapeutic ionizing radiation on lymphocyte activation within the tumor microenvironment are diverse. Summarized in Table 1 , [7] [8] [9] [10] [11] 29, 30 most studies evaluating the effects of ionizing radiation on T-lymphocyte function within the tumor microenvironment describe some degree of antitumor activation, although similar to the effects of ionizing radiation on dendritic cell function, these effects seem to be dose/ fractionation and model dependent. 31 Some consistent trends do emerge from the existing preclinical studies on the effects of ionizing radiation of Tlymphocytes. Tumor growth control after ionizing radiation in immunocompetent mouse models seems to be partially or totally dependent on the presence and function of CD8 1 cells, 9, 11, 23 suggesting that CD8 T-lymphocytes play a critical role in the cumulative effect of ionizing radiation on tumors. Clearly, dose and fractionation schedules of ionizing radiation have an impact on primary and abscopal tumor control, as several studies have demonstrated control of tumor growth or rejection of established tumors after single high-dose ionizing radiation but not after fractionated ionizing radiation. [9] [10] [11] Overall, fewer studies have evaluated the impact of low-dose, daily fractionated ionizing radiation on antitumor immunity. This has obvious implications for the study of HNSCC, as these patients are treated with 35 daily fractions of 1.8 to 2.0 Gy. Preclinical studies evaluating Tlymphocyte tumor repopulation after different doses and fractionation schemes of ionizing radiation are lacking and may provide information critical to the design of therapeutic regimens utilizing ionizing radiation to activate or enhance antitumor immunity.
| Mediators of immunosuppression within the tumor microenvironment
Although T-lymphocyte responses rely upon the presence and recognition of tumor-associated or tumor-specific antigen, most tumors likely harbor many genetic alterations that result in a number of neoantigens with a high degree of clonality. 32 Taking this and antigen-independent NK cytotoxicity into account, 33 it is likely that the ability of solid tumors to develop a directly immunosuppressive microenvironment plays a critical role in the outgrowth of clinically relevant malignancies. 34, 35 This immunosuppressive tumor microenvironment can be mediated by tumor, stromal, and infiltrating immune cells. Tumor cell-intrinsic mechanisms include downregulation of major histocompatibility (MHC) class I and antigen-processing machinery, genetic alterations leading to insensitivity to granzyme B and tumor necrosis factor receptor (TNFR) superfamily-induced apoptosis, and increased expression of cell surface molecules that inhibit cytotoxic T lymphocytes (CTLs) (programmed death-ligand 1 [PD-L1]). Tumor cells secrete immunosuppressive cytokines, such as transforming growth factor-beta and IL-10 that inhibit dendritic cell activation and T-lymphocyte function. Tumor cells also express chemokines that drive the recruitment of hematopoietic cells into the tumor that are immunosuppressive. These include myeloid-derived suppressor cells, M2-polarized tumor-associated macrophages (M 2 ), and regulatory CD4 1 T-lymphocytes (Tregs). Via mechanisms, such as local nutrient depletion, cytokine and immune checkpoint expression, and generation of reactive oxygen species, these cell types potently suppress effector CTL and NK functions.
| Myeloid-derived suppressor cells
Deng et al 36 
| Regulatory T-lymphocytes
Irradiation of TUBO tumors with 12 Gyx1 did not significantly alter tumor infiltration of Tregs. 36 Conversely, in an intracranial glioma model, 10 Gyx1 did reduce infiltration of Tregs into the brain microenvironment. 30 Interestingly, 8
Gyx3 ionizing radiation treatment of MC38 colon carcinomas did not significantly reduce Treg accumulation of primary treated tumors but did decrease Treg accumulation in contralateral untreated tumors. 38 A commonly cited article details the ionizing radiation dose-dependent increased percentages of CD251FoxP3 1 cells within the CD4 1 splenocyte compartment with single doses ranging from 5 to 15 Gy but this study did not evaluate tumor accumulation of Tregs. 8 Again, studies evaluating the effects of low-dose, daily fractionated ionizing radiation on peripheral or tumor accumulation of Tregs are lacking.
| Tumor-associated macrophages
Treatment of Panc02 tumors with 20 Gyx3 ionizing radiation resulted in increased accumulation of CD11b 1 cells that express immunosuppressive markers of M2-polarization, such as arginase and IL-10. 39 Similarly, exposure of TRAMP-C1 tumors to 25 Gyx1 or 4 Gyx15 results in selective accumulation of arginase, inducible nitric oxide synthase, and cyclooxygenase-2 expressing macrophages in areas of tumor hypoxia. 40, 41 Conversely, vascular normalization and accumulation of antigen-specific CD8 TIL was enhanced in insulinomas after a single dose of 2 Gy. This recruitment was dependent upon the presence of radiationinduced mature macrophages within the tumor microenvironment. 42 Understanding how different ionizing radiation doses and schemas alter macrophage function is challenging given their high plasticity and multiple functions.
| Tumor vasculature
At baseline, most solid tumors display disorganized and highly leaky tumor vasculature that ultimately contributes to tumor hypoxia and increased interstitial pressure, both of which are highly detrimental to the function of effector immune cells. 43 gantly detailed the necessity of eliminating CAFs to achieve complete tumor rejection. In the model system used by these groups, 10 Gyx1 induced enough antigen release from tumor cells that CAFs cross-presenting released tumor antigen were eliminated by adoptively transferred CTLs and this irradiation was required for sensitization of the CAFs to immune killing. 57 Clearly, immune elimination of both tumor and stromal cells is critical for tumor rejection.
| Direct effects on tumor cells
Ionizing radiation causes DNA damage, and could induce the formation of new mutations that could lead to the expression of neoantigens in irradiated cells. Reits et al 58 demonstrated that not only does ionizing radiation induce expression of MHC class I on the surface of tumor cells, it increases the intracellular pool of peptides available for loading onto MHC class I in an mTOR-dependent fashion. Some of these differentially presented peptides seemed to be derived from proteins selectively upregulated by irradiation. This suggests that if irradiation led to the formation of neoepitopes unique to irradiated cells, the MHC presentation pathways required for CTL recognition may also be upregulated by ionizing radiation. Others have demonstrated upregulation of MHC class I on the surface of tumor cells both in vitro and in vivo in mechanisms often dependent on increased levels of type II IFN. 45, 59 Immunogenic cell death, as defined by Kroemer et al. 60 includes the cell surface expression or release of molecules known to stimulate innate immune receptors to activate the innate arm of the immune system after a cytotoxic insult. 19, 61 This includes increased expression of cell surface calreticulin (binds CD91) and release of HMGB1 (binds toll-like receptor 4) and ATP (binds P2RX7). Whether ionizing radiation induces pure immunogenic cell death is unclear but more substantial evidence exists that ionizing radiation can induce tumor cells death associated with one or more immunogenic cell death components or release of other innate immunity activating molecules. 17, 63, 64 In addition to ionizing radiation inducing innate immune activation through induction of different components of immunogenic cell death, more recent work has highlighted the importance of cytosolic sensing of DNA (released from dying tumor cells) in dendritic cells through the STING receptor. Type I IFN production serves When damage after ionizing radiation is not sufficient to directly induce cell death, irradiated tumor cells seem to be more sensitive to CTL-mediated lysis. Garnett et al 59 demonstrated in a panel of CEA 1 colon carcinoma lines that sublethal ionizing radiation doses of 10 or 20 Gy enhanced tumor cell susceptibility to CTL lysis. Such "immunogenic modulation" to enhance CTL lysis after sublethal ionizing radiation in vitro has been demonstrated in many cancer cell types 65, 66 and seems to mechanistically be due to enhanced antigen presentation on MHC class I, enhanced intercellular adhesion molecule-mediated tumor:T cell interaction and enhanced cell surface calreticulin exposure. Some of the most powerful data demonstrating enhanced antigen-specific immune responses after ionizing radiation comes from studies on antigen-spread after peptide vaccination. After single-peptide vaccination of tumors expressing multiple MHC class I-restricted antigens, 8 Gyx1 ionizing radiation treatment induces the formation of T cell responses against multiple antigens resulting in rejection or control of both locally treated and distant untreated tumors. 67, 68 This data suggest that ionizing radiation enhances the presentation of multiple antigens, leading to the development of a polyclonal T cell response against antigens not attributable to the peptide vaccine directly. This concept was reinforced by a recent study in B16-F10 melanoma tumors demonstrating increased diversity of T cell receptor clones in CD8 1 TIL from irradiated compared to nonirradiated tumors. 69 1.12 | What is the preclinical evidence for radiation 1 checkpoint inhibition?
The rational combination of ionizing radiation and PD-based immunotherapy stems from a fundamental understanding of the mechanism of PD-based checkpoint inhibition and evidence that ionizing radiation may actually induce an innate and adaptive antitumor immune response, as described above. The PD-based immune checkpoint blockade reverses adaptive immune resistance. 70 To our knowledge, there are no data to suggest that PD-1 or PD-L1 monoclonal antibody (mAb) treatment can induce a de novo immune response. 71 If baseline or treatment-induced antitumor immunity is present within an organism and being held back by PD-1/PD-L1 signaling, then PD-blockade can potentially block this signaling and unleash this existing immune response. If another therapy, such as ionizing radiation, can actually induce an immune response and there is evidence that this induced immune response is being blocked by the induced expression of PD-pathway components, then the combination of this therapy and PD-based immune checkpoint blockade is rational. Evidence that ionizing radiation can induce that then drives PD-L1 expression, consistent with adaptive immune resistance. The principles underlying enhanced antitumor immunity after cytolytic T lymphocyte associated antigen 4 (CTLA-4)-based checkpoint inhibition are different. As opposed to PD-1/PD-L1 expression in response to IFN and immune activation as a mechanism of adaptive immune resistance, CTLA-4 seems to be constitutively expressed at varying levels on effector CD8 TIL and tumor infiltrating Tregs. Blockade of CTLA4 signaling with CTLA-4 mAb both blocks the negative signal mediated by CTLA-4 on effector CD8 TIL but also results in macrophage-dependent antibody-dependent cellular cytotoxicity elimination of CTLA-4 1 Tregs. [73] [74] [75] Both mechanisms are required to enhance antitumor immunity. 75 Subsequently, evidence suggests that the CTLA-4 immune checkpoint blockade can actually activate an immune response, as opposed to just unblocking a preexisting response. 74, 75 Although the CTLA-4 immune checkpoint blockade is still simply a tool to enhance antitumor immunity, the mechanism of how it may be additive or synergistic with ionizing radiation is likely different than when ionizing radiation is combined with the PD-based immune checkpoint blockade. alone, abscopal control of distant tumors after combination therapy provides strong evidence for the development of systemic antitumor immunity. One significant study elegantly demonstrated that combination 20 Gyx1 ionizing radiation plus CTLA-4 immune checkpoint blockade leads to increased PD-L1 expression on tumor cells. 69 Tumor rejection rates could be significantly enhanced by reversing adaptive immune resistance with the addition of PD-based immune checkpoint blockade to ionizing radiation plus CTLA-4 mAb, reinforcing many of the principles discussed above.
| What is the clinical evidence for radiation 1 checkpoint inhibition?
Several case reports have demonstrated control of nonirradiated tumors after irradiation of target lesions with hypofractionated ionizing radiation in the presence of systemic CTLA-4 mAb (Table 3) . [77] [78] [79] [80] Although abscopal tumor control cannot be completely attributed to radiation given that patients are receiving systemic CTLA-4 mAb, many of these reports demonstrate some degree of abscopal control of nonirradiated tumors in the setting of progression while receiving CTLA-4 mAb, suggesting a critical role for irradiation in the induction of systemic immunity. To date, no clinical data describing results after combination ionizing radiation and immune checkpoint blockade in head and neck cancer has been published. However, many clinical trials specific for HNSCC or in solid tumors that include HNSCC are underway (Table 4) . How different ionizing radiation dose and fractionation schemas alter local antitumor immunity to be additive or synergistic with immune checkpoint blockade is a critical question. Although the majority of preclinical data suggests that individual large or hypofractionated ionizing radiation doses seem to enhance local antitumor immunity to a greater degree than daily fractionated ionizing radiation, we must remember that our preclinical models simply serve as models for what may happen in patients with HNSCC. Despite these preclinical data, several institutions are moving forward with HNSCC trials investigating immune checkpoint blockade combined with standard, low-dose, daily fractionated (Table  4 trials 1-7) and higher-dose hypofractionated ionizing radiation (Table 4 trials 9-11). Clinical and immune correlative data emerging form these trials in the coming years as they mature will be very informative and should help guide the design of large phase trials designed to more clearly define the role of combination ionizing radiation and immune checkpoint blockade in both recurrent/metastatic and previously untreated, locally advanced HNSCC.
| CON CLU S IO NS
The emergence of checkpoint inhibitors as an Food and Drug Administration-approved, off-the-shelf immunotherapy with reasonable safety profiles has helped usher in the current age of immunotherapy for cancer. Along with our enhanced mechanistic understanding of how these drugs work is the realization that the combination with other anticancer therapies that have the capacity to induce immune responses is likely needed to meaningfully enhance response rates. Based upon extensive preclinical data, ionizing radiation fills this role well. There is a tendency, however, to combine new therapies (checkpoint inhibitors) with current standard of care therapies (low-dose daily fractionated Abbreviations: CTLA-4, cytolytic T lymphocyte associated antigen 4; DFS, disease-free survival; DLT, dose-limiting toxicity; HNSCC, head and neck squamous cell carcinoma; IMRT, intensity-modulated radiotherapy; LRC, locoregional control; mAb, monoclonal antibody; Mel, xxx; NCT, National Center for Tumor; NSCLC, nonsmall cell lung cancer; ORR, overall response rate; PD-1, programmed death-1; PD-L1, programmed death ligand-1; PFS, progression-free survival; PULA, previously untreated, locoregionally advanced; RCC, renal cell carcinoma; RT, radiotherapy; SBRT, stereotactic body radiotherapy; SCC, squamous cell carcinoma.
ionizing radiation, in the case of HNSCC) without supporting preclinical data. Indeed, the majority of published preclinical data supports that single high-dose or hypofractionated ionizing radiation enhances local antitumor immunity and is either additive or synergistic with either PDbased or CTLA-4-based immune checkpoint blockade. However, preclinical data supporting the combination of lowdose, daily fractionated ionizing radiation with immune checkpoint blockade is at best lacking and at worst negative. Clearly, mechanistic preclinical studies investigating how different radiation schemas perform head-to-head when combined with immune checkpoint blockade are needed to inform the data-driven design of clinical trials. Although many current clinical trials combining ionizing radiation and immune checkpoint blockade are designed to assess safety as a primary endpoint, secondary immune correlative and clinical response outcomes will certainly assist in the design of future trials aimed at enhancing response rates for patients with HNSCC. 
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